SHILPA MEDICARE LTD. - 530549 - Outcome Of Securities Issue Committee
Outcome of Securities Issue committee on allotment of equity shares13-04-2024
13-04-2024
SHILPA MEDICARE LTD. - 530549 - Securities Issue Committee Meeting On Determination Of Issue Price
outcome of Securities Issue committee meeting on approval of closure of issue, determination and allocation of equity shares and an issue price12-04-2024
Shilpa Medicare Sets Issue Price For Rs 500-Crore QIP
The QIP will result in equity dilution of 11.24% after the issue.08-04-2024
SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Qualified Institutional Placement
Prior Intimation for Determination of issue price08-04-2024
SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Qualified Institutional Placement
Outcome of meeting of Securities issue committee08-04-2024
SHILPA MEDICARE LTD. - 530549 - Appointment Of Mr. Santosh Kumar Mahil As CEO Of Shilpa Pharma Lifesciences Limited, A Wholly Owned Subsidiary Of Shilpa Medicare Limited
Appointment of Mr. Santosh Kumar Mahil as CEO of Shilpa Pharma Lifesciences Limited, a wholly owned subsidiary of Shilpa Medicare Limited28-03-2024
SHILPA MEDICARE LTD. - 530549 - Closure of Trading Window
Closure of Trading window notice28-03-2024
SHILPA MEDICARE LTD. - 530549 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Declaration of Postal Ballot results and Scrutinizers report with respect to Issue of Securities by way of QIP14-03-2024
SHILPA MEDICARE LTD. - 530549 - USFDA Inspection Of Bio-Analytical Laboratory, Unit 7, Shilpa Medicare Limited, Nacharam, Hyderabad
USFDA Inspection of Bio-Analytical Laboratory, Unit 7, Shilpa Medicare Limited , Nacharam, Hyderabad, Telangana01-03-2024
SHILPA MEDICARE LTD. - 530549 - Europe Approval For Varenicline Tablets
Europe Approval for Varenicline Tablets, 0.5 mg and 1mg26-02-2024